Welcome to our dedicated page for Dyadic Intl Del SEC filings (Ticker: DYAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dyadic International, Inc. (DYAI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Dyadic, doing business as Dyadic Applied BioSolutions, is a global biotechnology company that uses proprietary C1 and Dapibus™ microbial platforms to produce recombinant, animal-free proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets.
Through this page, users can review Dyadic’s Forms 10-K and 10-Q for detailed discussions of its business, risk factors, microbial expression platforms, collaborations, and financial performance. These periodic reports explain how the company generates revenue from research and development contracts, grants, licenses, milestones, and commercial activities related to its recombinant protein portfolio.
Investors can also examine Dyadic’s Form 8-K current reports, which disclose material events such as equity offerings under its shelf registration statement, Nasdaq listing deficiency notices and subsequent compliance updates, commercial agreements, corporate rebranding to Dyadic Applied BioSolutions, and strategic presentations describing its transition from R&D to commercial operations.
In addition, this page is the place to track any proxy statements and shareholder meeting results, including votes on director elections, auditor ratification, and advisory votes on executive compensation and its frequency. These filings provide insight into Dyadic’s governance practices and shareholder decisions.
Stock Titan enhances Dyadic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand complex sections of 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new filings appear promptly, while structured views of ownership and transaction reports, such as Form 4 insider trading disclosures when available, allow closer monitoring of insider activity.
By combining Dyadic’s original SEC documents with AI-generated explanations, this page helps investors, researchers, and other stakeholders navigate the company’s regulatory history, capital markets actions, and evolving commercial strategy around its C1 and Dapibus™ protein production platforms.
Dyadic International, Inc. reported results for the quarter ended June 30, 2025, showing revenue growth and a smaller operating loss versus the prior year. Total revenue was $966,630 for the quarter (versus $385,896 a year earlier) and $1,360,202 for the six months (versus $720,513). Net loss for the quarter was $(1,793,774) compared with $(2,045,223) a year ago; six-month net loss was $(3,821,353) versus $(4,054,819). Basic and diluted loss per share was $(0.06) for the quarter and $(0.13) for six months.
Balance sheet and liquidity highlights show cash and cash equivalents of $2,140,899 and restricted cash of $1,833,531 related to the Gates Foundation grant. Total assets were $8.14 million and total liabilities $8.67 million, producing stockholders' equity of $(529,701). Convertible notes net carrying amounts were $1,070,971 (related party) and $3,930,170 (third party). Post-period the company closed an offering on August 1, 2025 that generated net proceeds of approximately $5.3 million; management states existing funds plus the offering are expected to cover at least 12 months, subject to assumptions stated in the filing.
Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).
The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.
Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.
Dyadic International (NASDAQ:DYAI) filed an 8-K disclosing receipt of a Nasdaq Listing Rule 5550(b)(2) deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities (MVLS).
The stock has been below the threshold for 30 consecutive business days, activating a 180-day cure period ending December 20, 2025. To regain compliance, DYAI’s MVLS must close at or above $35 million for at least 10 consecutive trading days before the deadline. Failure would prompt a delisting determination, which the company could appeal, though success is not assured.
The notice has no immediate effect on Nasdaq trading but flags heightened liquidity and financing risk. Management says it will monitor MVLS and “evaluate available options,” yet outlines no specific actions. Forward-looking statements reiterate ongoing losses, capital needs, and potential breaches of other listing standards, underscoring uncertainty for shareholders.
Dyadic International, Inc. (NASDAQ: DYAI) filed an 8-K to disclose the final results of its 20 June 2025 Annual Meeting of Shareholders.
- Director election – Class III: Founder & CEO Mark A. Emalfarb was re-elected to serve until the 2028 meeting with 15,946,385 votes FOR (96.0% of votes cast) versus 421,896 WITHHELD and 7,892,709 broker non-votes.
- Auditor ratification: Crowe LLP was confirmed as independent registered public accounting firm for FY-2025 with an overwhelming 24,013,307 FOR (99.0%), 237,523 AGAINST and 10,160 ABSTAIN.
- Say-on-pay (advisory): Compensation of named executive officers received 15,765,072 FOR (95.9%), 522,744 AGAINST, 80,465 ABSTAIN, and 7,892,709 broker non-votes.
- Say-on-pay frequency: Shareholders strongly preferred an annual advisory vote: 15,443,558 votes for 1-year, handily exceeding 716,692 (2-years) and 13,576 (3-years). Abstentions were 194,455.
Based on these results, the Board and its Compensation Committee have resolved that future advisory votes on executive compensation will be held once every year.
No other matters were brought before the meeting, and there were no disclosures of earnings, major transactions or material events beyond the voting outcomes.
FAQ
What is the current stock price of Dyadic Intl Del (DYAI)?
What is the market cap of Dyadic Intl Del (DYAI)?
